FRANKFURT AM MAIN, GERMANY - OCTOBER 21: A man walkes in front of Lufthansa airplanes at the Frankfurt Airport on October 21, 2014 in Frankfurt am Main, Germany. Vereinigung Cockpit, the labor union that represents the pilots, launched the two-day strike yesterday that has been expanded from short and medium-distance flights on the first day to long haul flights today, affecting over 100,000 passengers. This is the seventh strike by Lufthansa and Germanwings (a Lufthansa subsidiary) pilots this year as the union attempts to maintain the Lufthansa pilots' early retirement guarantee, a benefit that Lufthansa is trying to cut. (Photo by Thomas Lohnes/Getty Images)

Boston Scientific Corporation (NYSE:BSX) stock is presently standing at about $23.61 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 22 analysts covering the company is $28.00, which suggests the stock could still rise over 16 percent. The highest analyst price target is $31.00, which implies a rally of 69 percent. And a quick view of analyst notes show that 12 are rating the stock a buy while 9 rate BSX a strong buy. There are 5 equity research firms advocating a Hold and 0 consider it Sell.

Argus analysts provided their view on Boston Scientific Corporation (NYSE:BSX) recently. The rating firm issued a Buy rating to this company in a research note released on Sep 01, 2016. Guggenheim analysts disclosed their opinion on Boston Scientific Corporation (NYSE:BSX) recently. The rating firm gave a Buy rating to this stock in a research note published on Jun 09, 2016. According to a research note disclosed on Oct 05, 2015, analysts at Raymond James have upped their rating on these shares from Outperform to Strong Buy.

Boston Scientific Corporation (NYSE:BSX) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its EVP, GC & Chief Admin Officer Pratt Timothy A. sold 6,195 company shares for $137000.78, in a transaction on 2017-01-09. Following the transaction, the EVP, GC & Chief Admin Officer is left with a stake of 137.78 shares, currently valued at $3253. Meanwhile, SVP and President, Endoscopy Pierce David A sold 10,232 shares worth $227000.56, through a transaction dated 2017-01-09. Following the completion of the transaction, the insider is left with a stake of 25,600 shares, amounting $604416. BSX EVP, GC & Chief Admin Officer Pratt Timothy A. also sold 26,726 shares, at a stock price of $20.48. This transaction occurred on 2016-12-01 totals $547000.35. After this transaction, the insider’s stake stands at 233,704 shares, with a market value of $5517751.

Executives hold 0.79 percent of the stock. Pete M. Nicholas is one of the biggest insider owners in Boston Scientific Corporation (NYSE:BSX), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 3,486,965 shares which have current market value of around $82327243.65.Mr. Michael F. Mahoney is another major inside shareholder in the company. The insider owns 1,601,858 shares as of 0.12%, currently worth $37819867.38. Mr. J. Raymond Elliott is ranked as third insider holder of the stock. This insider holds 603,676 shares with a market value around $14252790.36 as of recent close.

Boston Scientific Corporation (NYSE:BSX) Earnings Outlook

In Boston Scientific Corporation (NYSE:BSX)’s latest quarter, EPS moved to $0.27 from $0.27 in preceding quarter and revenues reached at $2,105.00M compared to $2,126.00M. Analysts had expected Boston Scientific Corporation (NYSE:BSX) to post net income of about $0.27 per share on $2,070.86M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $0.29 to $0.32. That is compared with the $0.26 in EPS it reported during the same period a year ago.